Ocugen, Inc. OCGN shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.OCGN shares are powering higher on strong volume. Find out why here.What To Know: Ocugen said it executed a licensing agreement with Kwangdong for rights to OCU400, its modifier gene therapy for retinitis pigmentosa. The deal marks Ocugen's first regional partnership for the program.Under the agreement, Ocugen will receive upfront license ...